Literature DB >> 15037262

Skip metastases: analysis of their clinical significance and prognosis in the IIIA stage of non-small cell lung cancer.

P Misthos1, E Sepsas, K Athanassiadi, S Kakaris, I Skottis.   

Abstract

OBJECTIVE: To determine the clinical significance of skip metastases (pN2/S) in patients with resected pIIIA/N2 NSCLC. The incidence of pN2/S after mediastinal lymph node dissection (MLD) and sampling (MLS) were compared.
METHOD: From 1997 to 2000, 580 lung resections for NSCLC performed at our department. The 151 patients (26.5%) at stage IIIA/N2 (pN2+) were grouped according to their skip metastases status. Group A included the ordinary pN2 (pN2/O) cases (71%) and group B the pN2/S (29%). Age, gender, type of resection, right or left lesion, histology, tumor lobe predilection, MLD or MLS pathologic results, the level and the number of node stations involved and survival were analyzed.
RESULTS: In 44 patients (29%) pN2/S disease was present. Statistical analysis revealed significant difference between pN2/O and pN2/S for the following: (1) pN2/S was more common for right-sided lesions (P=0.007); (2) Squamous carcinoma was the main type of pN2/S (P=0.007) and (3) pN2/S was more frequently detected after MLD than after MLS (P=0.001). Although pN2/S involved more often upper mediastinal lymph nodes (Nos. 2, 3) and one station level (pN2/S: 41 vs. pN2/O: 19.6%, P=0.228) was not found statistically significant. pN2/O was more common after right upper lobectomy and pN2/S after right lower lobectomy. The 3-year survival was more favorable for the pN2/S group (A: 24 vs. B: 36%, P=0.07).
CONCLUSION: (1) MLD was found to be more reliable for pN2/S detection than MLS. (2) The presence of pN2/S proved to be a less aggressive form of lymphatic spread that should be taken into account in the future. (3) Strong correlation between right lower lobe tumors and pN2/S was demonstrated. (4) Different routes of cancer lymphatic spread between pN2/S and pN2/O are suggested.

Entities:  

Mesh:

Year:  2004        PMID: 15037262     DOI: 10.1016/j.ejcts.2004.01.025

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  18 in total

1.  Mediastinal lymphatic drainage from pulmonary lobe based on CT observations of histoplasmosis: implications for minimal N2 disease of non-small-cell lung cancer.

Authors:  Koji Takahashi; William Stanford; Edwin Van Beek; Brad Thompson; Brian Mullan; Yutaka Sato
Journal:  Radiat Med       Date:  2007-10-26

2.  Has lobe-specific nodal dissection for early-stage non-small lung cancer already become standard treatment?

Authors:  Tomohiro Maniwa; Ken Kodama
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

3.  CT-guided needle biopsy in the diagnosis of lung adenocarcinoma accompanied by extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue: a rare combination.

Authors:  Panwen Tian; Ye Wang; Chun Wan; Yongchun Shen; Fuqiang Wen
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

4.  Which subgroup of patients with pathologic N2 non-small cell lung cancer benefit from surgery?

Authors:  Yasunobu Funakoshi; Yukiyasu Takeuchi; Hidenori Kusumoto; Toru Kimura; Hajime Maeda
Journal:  J Cancer Res Clin Oncol       Date:  2012-02-25       Impact factor: 4.553

5.  Upfront surgery in patients with clinical skip N2 lung cancer based on results of modern radiological examinations.

Authors:  Tomohiro Maniwa; Yasushi Shintani; Jiro Okami; Yoshihisa Kadota; Yukiyasu Takeuchi; Koji Takami; Hideoki Yokouchi; Eiji Kurokawa; Ryu Kanzaki; Yasushi Sakamaki; Hiroyuki Shiono; Teruo Iwasaki; Kiyonori Nishioka; Ken Kodama; Meinoshin Okumura
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

6.  Analysis of factors influencing skip lymphatic metastasis in pN(2) non-small cell lung cancer.

Authors:  Gui-Long Li; Yong Zhu; Wei Zheng; Chao-Hui Guo; Chun Chen
Journal:  Chin J Cancer Res       Date:  2012-12       Impact factor: 5.087

7.  Detection of alternative subpleural lymph flow pathways using indocyanine green fluorescence.

Authors:  Aya Harada Takeda; Yui Watanabe; Toshiyuki Nagata; Masaya Aoki; Tadashi Umehara; Soichi Suzuki; Go Kamimura; Kazuhiro Wakida; Tsunayuki Otsuka; Naoya Yokomakura; Kota Kariatsumari; Koichi Sakasegawa; Yoshihiro Nakamura; Masami Sato
Journal:  Surg Today       Date:  2018-01-30       Impact factor: 2.549

8.  Outcomes of initial surgery in patients with clinical N2 non-small cell lung cancer who met 4 specific criteria.

Authors:  Tomohiro Maniwa; Shoji Takahashi; Mitsuhiro Isaka; Masahiro Endo; Yasuhisa Ohde
Journal:  Surg Today       Date:  2015-11-02       Impact factor: 2.549

Review 9.  Lymph node dissection for lung cancer: past, present, and future.

Authors:  Shun-ichi Watanabe
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-05-15

10.  Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer.

Authors:  Jun Zhao; Jiagen Li; Ning Li; Shugeng Gao
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.